Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-01-11 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于哈药集团增资事宜获得哈尔滨市人民政府批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase (增资) involving the company 哈药集团股份有限公司 and its controlling shareholders. It details the approval from the Harbin municipal government and changes in shareholding percentages due to the capital injection by 中信资本医药. The text focuses on the transaction and ownership structure changes rather than presenting financial statements or detailed financial performance data. The document length is short (1403 characters) and it is clearly an announcement of a financing event rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-01-11 Chinese
重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产重组进展公告" which translates to "Major Asset Restructuring Progress Announcement." It details ongoing progress and updates related to a significant asset restructuring involving the company and its subsidiary. The text references multiple prior announcements and meetings related to the restructuring, including board meetings, shareholder meetings, and regulatory filings. The document is relatively short (2181 characters) and focuses on providing updates about the progress of the restructuring rather than presenting full financial statements or detailed financial analysis. It is clearly an announcement about the progress of a major asset restructuring, not the restructuring report itself or a merger filing. According to the filing definitions, announcements about progress on major asset restructuring fall under Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2018-01-10 Chinese
关于上海证券交易所《关于对哈药股份实际控制人拟发生变更等事项的问询函》的回复公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement and response regarding a significant change in the actual control of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) due to a capital increase and acquisition by 中信资本控股 (CITIC Capital Holdings). It discusses the background, process, and regulatory compliance of the transaction, including the relationship to a major asset restructuring and the triggering of a mandatory tender offer. The document includes detailed disclosures about the transaction pricing, funding sources, and regulatory considerations. It is not a full annual or interim financial report, nor is it a simple announcement or presentation. It is a comprehensive regulatory disclosure related to a major capital and control change event, fitting the category of Capital/Financing Update (CAP).
2018-01-09 Chinese
关于部分限制性股票回购注销结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 哈药集团股份有限公司 regarding the results of a repurchase and cancellation of restricted shares. It details the approval of the repurchase, the number of shares repurchased and cancelled, and the resulting changes in the company's share capital. The document is short (1198 characters) and focuses on a specific capital change event rather than providing comprehensive financial data or a full report. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or share cancellations. It is not an annual report, interim report, or any other type of financial report, nor is it a simple announcement of a report publication. Therefore, the correct classification is POS.
2018-01-09 Chinese
要约收购报告书摘要（修订稿）
M&A Activity Classification · 100% confidence The document is titled as a "要约收购报告书摘要" which translates to "Tender Offer Report Summary" or "Offer to Purchase Report Summary." It details a comprehensive tender offer by CITIC Capital Holdings Limited and its subsidiaries to acquire shares of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). The document includes detailed information about the offeror, the target company, shareholding structures, the purpose of the offer, regulatory approvals needed, and financial arrangements for the tender offer. It is a formal disclosure related to a takeover bid or acquisition proposal. This type of document corresponds to filings related to M&A activity, specifically tender offers and takeover bids. It is not an annual report, earnings release, or other financial report. It is not a proxy solicitation or voting results announcement. The document is substantive and lengthy (15,000 characters), containing detailed information about the transaction and parties involved. Therefore, the appropriate classification is "TAR" (M&A Activity).
2018-01-09 Chinese
平安证券关于《上海证券交易所关于对哈药股份实际控制人拟发生变更等事项的问询函》之专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special investigation opinion report by Ping An Securities Co., Ltd. regarding an inquiry letter from the Shanghai Stock Exchange about changes in the actual controller of Harbin Pharmaceutical Group Co., Ltd. It discusses in detail the background, process, and implications of a major equity acquisition and capital increase involving CITIC Capital and Harbin Pharmaceutical Group, including compliance with regulatory requirements, pricing, and control rights. The document contains extensive factual and procedural information about the transaction, including dates, parties involved, regulatory references, and financial details. It is not a brief announcement or a simple notice but a comprehensive report on the investigation and verification of the transaction and related matters. This fits the category of an Audit Report / Information (AR), as it is a standalone report providing audit-like verification and opinions on a regulatory inquiry and transaction compliance, rather than a full annual report, earnings release, or other categories. The length (15,000 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2017
2018-01-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.